Back to Clinical Research

Genentech CHROMA

Status: Not Enrolling Identifier: NCT02745119

Genentech CHROMA: A Phase III, Multicenter, Randomized, Double-masked, Sham-controlled Study to assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

Condition: Geographic Atrophy secondary to AMD

Study Type: Interventional

Duration: 2 years


  • Ages: Child, Adult, Senior
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information, please click here

Back to Clinical Research